PureTech appoints Kiran Mazumdar-Shaw to Board of Directors

She will become a member of the board's Remuneration and Nomination Committees

PureTech Health, a clinical-stage biotherapeutics company, announced the appointment of Kiran Mazumdar-Shaw to its board of directors. Shaw is the founder and chairperson of Biocon.

“Driven by a commitment to provide access to life-saving medicines worldwide, Ms Shaw brings extensive experience in biotherapeutics, strategic leadership, financial and business development and a dedication to improving patients’ lives to PureTech’s board of industry leaders,” said a statement from the company.

“Kiran is a tremendously successful entrepreneur in healthcare and widely recognised as one of the most powerful and influential women in business. She also has a keen interest in improving the health of people around the world,” said Christopher Viehbacher, chairman of PureTech’s board of directors. “

“I am thrilled to join the luminaries on PureTech’s board at a time when the company is poised for rapid growth building on the many successes of recent years. With a unique and extremely productive approach towards the development of new medicines, the PureTech team has developed an impressive track record of pioneering new therapies, all of which could be transformational across a number of fields. With exciting programs within its Wholly Owned Pipeline, PureTech has the potential to be truly disruptive in addressing serious diseases where there is significant need,” said Shaw.

Daphne Zohar, founder and chief executive officer of PureTech. “Her (Shaw) proven track record of entrepreneurial ingenuity and integrity along with her demonstrated business leadership position her as an excellent addition to PureTech’s board of industry leaders. We are excited to work with her as we continue on our growth trajectory.”

On joining the board, Shaw will become a member of the board’s Remuneration and Nomination Committees.

BioconHRKiran Mazumdar-Shawnew appointmentPureTech Health
Comments (0)
Add Comment